GIP and obesity due to melanocortin 4 receptor deficiency: Trials investigating newer potential anti-obesity medications, including co-agonists and tri-agonists that target peptides such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), amylin, and glucagon are underway.